Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000554

Drug Information
NameFluvastatin
SynonymsFluvastatinum; T6624179; 93957-54-1; (E)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; Fluvas (TN); (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; Fluvas; HMS2089P06; BPBio1_000965; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; Fluvastatin [INN:BAN]; (3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; CID446155; CHEBI:38562; CID146801; XU 62320; BSPBio_000877; BRD-K03602135-236-02-1; I06-2297; CID5353627; nchembio.301-comp9; CID6914285; C24H26FNO4; 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)- 3,5-dihydroxy-, (3R,5S,6E)-rel-; CHEBI:38565; Fluvastatin & Primycin; CID1548972; CID3403; CID10501876; Fluvastatine; AC1L9J7I; (+)-(3R,5S)-fluvastatin; (E,3S,5R)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; XU-62320; Prestwick1_000859; Fluvastatinum [INN-Latin]; Fluvastatine [INN-French]; AC1NS4EB; CHEBI:38567; 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-, (R*,S*-(E))-(+-)-; CHEMBL1078; CPD001453708; Prestwick3_000859; Fluvastatin (INN); (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; CHEBI:5136; MolPort-003-847-470; Cranoc; Prestwick0_000859; AC1Q1PZO; D07983; nchembio790-comp18; BIDD:GT0839; (Z,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; Lescol XL; Fluindostatin; UNII-4L066368AS; CID9887837; (6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; LS-7404; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; TL8005940; (-)-(3S,5R)-fluvastatin; 7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; AC1LU7LJ; SPBio_002798; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; AC1L3TXK; Fluvastatina; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; CHEMBL170417; 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)- 3,5-dihydroxy-, (R*,S*-(E))-(+-)-; C07014; DB01095; Fluvastatina [INN-Spanish]; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; fluvastatin; Lescol; Prestwick2_000859; 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3R,5S,6E)-; AC1L1FUW; SAM002548940; Canef; AC1OC9O5
Trade NameLescol; Canef; Vastin
IndicationHypercholesterolemia
[ICD9: 272.0   ICD10: E78.0]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16
)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-
14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1/i24+2
InChIKeyFJLGEFLZQAZZCD-IMMLURFHSA-N
Canonical SMILESCC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F    
Isomeric SMILESCC(C)N1C2=CC=CC=C2[14C](=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F
Therapeutic ClassAnticholesteremic Agents
CAS NumberCAS 93957-54-1
FormulaC24H26FNO4
PubChem Compound IDCID 10501876.
PubChem Substance IDSID 15526875.
ChEBI5136;
SuperDrug ATC IDC10AA04
SuperDrug CAS ID093957541;
Target3-hydroxy-3-methylglutaryl-coenzyme A reductaseInhibitor[2]
Ref 1Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. To Reference
Ref 2Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543